Clarithromycin (Biaxin)

Clarithromycin, marketed under the brand name Biaxin, is a semi-synthetic macrolide antibiotic that serves as a critical treatment option for Rhodococcus equi pneumonia in foals. As a human-approved medication used off-label in equine practice, clarithromycin has established itself alongside azithromycin as a first-line macrolide for R. equi infections due to its excellent intracellular penetration, reliable absorption, and proven clinical efficacy when combined with rifampin. The availability of clarithromycin provides veterinarians with an important alternative when treating this life-threatening foal disease.

The mechanism of action of clarithromycin involves binding to the 50S ribosomal subunit of susceptible bacteria, thereby inhibiting bacterial protein synthesis. This interference with protein production prevents bacterial growth and reproduction, effectively halting the infectious process. Clarithromycin demonstrates primarily bacteriostatic activity at typical therapeutic concentrations, though bactericidal effects may occur at higher concentrations against certain susceptible organisms. The drug's exceptional ability to concentrate within phagocytic cells, achieving intracellular concentrations many times higher than plasma levels, makes it particularly effective against intracellular pathogens like Rhodococcus equi.

Clarithromycin is available in immediate-release tablets, extended-release tablets, and oral suspension formulations, providing flexibility for administration to foals of various sizes. The drug demonstrates good oral bioavailability in horses, allowing for reliable absorption when administered enterally. Standard clarithromycin requires twice-daily dosing due to its shorter half-life compared to azithromycin, though this more frequent administration may achieve more consistent tissue concentrations during the treatment course. The extended-release formulation is designed for once-daily dosing in humans but requires veterinary evaluation for appropriate use in equines.

The safety profile of clarithromycin in horses warrants careful consideration, as macrolide antibiotics carry significant risks in equine patients. Like other macrolides, clarithromycin has been associated with potentially fatal hyperthermia in foals, particularly during hot weather, and poses substantial risk of colitis in adult horses. These serious adverse effects limit clarithromycin use primarily to foals where the drug is genuinely indicated, and environmental management during treatment is essential to minimize hyperthermia risk. Veterinary supervision throughout the treatment course ensures appropriate monitoring and timely intervention if adverse effects develop.

The primary indication for clarithromycin in equine medicine is the treatment of Rhodococcus equi pneumonia in foals, either as an alternative to azithromycin or as the preferred macrolide in certain clinical situations. Rhodococcus equi causes severe pyogranulomatous pneumonia in foals, typically presenting between one and six months of age, with mortality rates historically exceeding fifty percent without appropriate antimicrobial therapy. Clarithromycin's excellent intracellular penetration allows the drug to reach R. equi organisms residing within pulmonary macrophages, where the bacteria evade host immune responses and many antibiotics.

Combination therapy with rifampin is mandatory when using clarithromycin for Rhodococcus equi infections, just as with azithromycin. The clarithromycin-rifampin combination provides synergistic antibacterial activity while preventing the rapid emergence of rifampin-resistant R. equi strains that occurs when rifampin is used as monotherapy. Both macrolides combined with rifampin have demonstrated excellent clinical efficacy for R. equi pneumonia, and the choice between clarithromycin and azithromycin often depends on availability, cost considerations, and veterinary preference based on experience with each agent.

Beyond Rhodococcus infections, clarithromycin may be considered for other respiratory tract infections in foals caused by susceptible organisms. Bacterial pneumonia caused by organisms susceptible to macrolides, particularly intracellular pathogens or those in anatomical locations favored by macrolide tissue distribution, may respond to clarithromycin therapy. However, given the risks associated with macrolide use in horses, treatment should be reserved for confirmed or strongly suspected infections where clarithromycin's unique properties offer clear advantages over safer antibiotic alternatives.

Other potential applications for clarithromycin in foals include treatment of infections caused by Lawsonia intracellularis, the causative agent of equine proliferative enteropathy, though other antimicrobials are more commonly used for this indication. Certain soft tissue infections caused by susceptible bacteria, particularly when intracellular organisms are suspected, may also respond to clarithromycin. The drug's tissue distribution characteristics support use in various anatomical locations, though clinical experience in horses is most extensive for respiratory applications.

Patient selection for clarithromycin therapy should be based on confirmed or strongly suspected susceptible infections, appropriate diagnostic workup, and careful assessment of risk-benefit considerations for the individual patient. The potential for serious adverse effects including hyperthermia and gastrointestinal complications means that clarithromycin should not be used empirically or for infections where safer antibiotics would be equally effective. On breeding farms with endemic Rhodococcus, screening programs enable early detection and timely intervention before infections progress to advanced, more difficult to treat stages.

Dosing of clarithromycin in foals for Rhodococcus equi infections follows established protocols based on pharmacokinetic studies and clinical experience, though veterinary determination of the appropriate regimen for each patient remains essential. Unlike azithromycin, which can be administered once daily or on a pulse schedule due to its prolonged tissue half-life, clarithromycin typically requires twice-daily administration to maintain therapeutic tissue concentrations throughout the dosing interval. Accurate foal weight measurement is critical for calculating appropriate doses and should be performed regularly as foals grow rapidly during the treatment period.

Standard clarithromycin dosing involves administration every twelve hours, providing consistent drug exposure throughout the day. The total daily dose is divided between morning and evening administrations, with each dose mixed with the concurrent rifampin dose in most treatment protocols. Treatment duration for R. equi pneumonia is typically extended, commonly lasting four to twelve weeks depending on initial disease severity and response to therapy. Serial monitoring through thoracic ultrasound and bloodwork guides decisions about treatment duration and helps identify appropriate endpoints for therapy discontinuation.

The oral suspension formulation of clarithromycin is most practical for administration to foals, allowing accurate dose measurement based on body weight. Suspension should be shaken thoroughly before each dose to ensure uniform drug distribution throughout the preparation. Administration via oral dosing syringe allows for controlled delivery, and foals often tolerate the medication better when slightly hungry. Some foals may show aversion to the taste, and various administration techniques may be needed to ensure complete dosing. Tablets can be crushed and suspended in water if liquid formulation is unavailable, though this is generally less convenient.

Timing of clarithromycin administration should maintain consistent twelve-hour intervals between doses to optimize drug concentrations. Administration with food may reduce gastrointestinal upset in some foals, though this is not strictly required. The concurrent rifampin dose is typically given at the same time as the clarithromycin for convenience and compliance. Establishing a consistent daily routine for medication administration helps ensure doses are not missed and maintains therapeutic drug levels.

If a dose of clarithromycin is missed, it should be given as soon as remembered unless the next scheduled dose is approaching. In that case, veterinary guidance should be sought regarding whether to skip the missed dose or adjust the schedule. Never double the dose to compensate for missed administration. Consistent adherence to the twice-daily schedule is more challenging than once-daily medications, and owners should establish reminder systems to maintain compliance throughout the extended treatment course.

Completion of the full prescribed treatment course is essential even when foals show clinical improvement before all medication is administered. Premature discontinuation risks treatment failure, disease relapse, and potentially selection of resistant organisms. The veterinarian determines appropriate treatment duration based on ongoing clinical assessment, ultrasound monitoring of pulmonary lesions, and normalization of inflammatory markers. Extended treatment beyond initial clinical improvement is typically necessary to achieve complete resolution of R. equi pneumonia.

Clarithromycin shares the significant adverse effect profile common to macrolide antibiotics in horses, requiring careful monitoring and risk management during treatment. The most serious concerns include hyperthermia in foals and fatal colitis in adult horses. Understanding these potential complications enables appropriate precautions and prompt intervention when problems develop. The overall risk-benefit assessment for clarithromycin use must account for these substantial adverse effect possibilities.

Hyperthermia represents the most immediately dangerous adverse effect of clarithromycin and other macrolides in foals. Affected foals develop dramatic elevations in body temperature that can rapidly become life-threatening, particularly during warm weather or with sun exposure. This idiosyncratic reaction does not appear to be directly dose-related and can occur unpredictably during treatment. Environmental management to minimize heat exposure is essential throughout the treatment course, and regular temperature monitoring allows early detection of developing hyperthermia before it becomes severe.

Gastrointestinal effects occur commonly with clarithromycin use and range from mild to severe. Decreased appetite, soft stool, and mild colic signs represent common, usually self-limiting effects that may improve as treatment continues. However, more severe gastrointestinal complications including significant diarrhea can develop. In adult horses, macrolide antibiotics carry substantial risk of fatal colitis due to disruption of hindgut microbial populations, which is why clarithromycin use is generally restricted to foals. Even in foals, careful observation of gastrointestinal function is warranted throughout treatment.

Hepatic effects may occur with clarithromycin use, particularly during prolonged treatment courses or when combined with rifampin, which is also metabolized hepatically. Elevations in liver enzymes may develop, and periodic monitoring of hepatic function through bloodwork may be recommended during extended therapy. Clinical signs of hepatic dysfunction including jaundice, anorexia, or behavioral changes warrant immediate veterinary evaluation and potential treatment modification.

Other potential adverse effects include allergic reactions manifesting as skin eruptions, facial swelling, or respiratory difficulty, though these are uncommon. Cardiac rhythm effects have been reported with macrolide antibiotics in some species, and clarithromycin may potentially cause QT prolongation. Any unusual symptoms, behavioral changes, or concerns during clarithromycin therapy should prompt communication with the attending veterinarian. The decision to continue, modify, or discontinue treatment must weigh adverse effects against the necessity of continued therapy for the underlying infection.

Clarithromycin is contraindicated in horses with known hypersensitivity to macrolide antibiotics. Previous allergic reactions to clarithromycin, azithromycin, erythromycin, or other macrolides represent absolute contraindications to clarithromycin administration, as cross-reactivity within the macrolide antibiotic class is common. Hypersensitivity reactions including skin eruptions, angioedema, respiratory difficulty, or anaphylaxis require permanent avoidance of all macrolide antibiotics. Complete medication history including adverse reactions should be reviewed with the veterinarian before initiating therapy.

The use of clarithromycin in adult horses is relatively contraindicated due to the substantial risk of fatal antibiotic-associated colitis. Mature horses are particularly susceptible to disruption of hindgut microbial populations by macrolide antibiotics, and resulting dysbiosis can trigger severe, often fatal diarrhea. While absolute prohibition does not exist, clarithromycin should only be considered in adult horses when no alternatives are available and the potential benefits definitively outweigh the considerable risk of life-threatening colitis. Virtually all clarithromycin use in equine practice is appropriately restricted to foals.

Horses with pre-existing gastrointestinal disease, recent antibiotic-associated diarrhea, or conditions predisposing to intestinal dysbiosis should generally not receive clarithromycin. Previous colitis from any cause increases susceptibility to antibiotic-triggered gastrointestinal complications. Even in foals, history of significant diarrhea or gastrointestinal disturbance may influence the decision to use clarithromycin versus alternative therapeutic approaches.

Hepatic impairment may affect clarithromycin metabolism and elimination, as the drug undergoes hepatic processing. Horses with known liver disease or elevated hepatic enzymes require careful evaluation before clarithromycin administration, and dose adjustment or selection of alternative therapy may be warranted. The combination with rifampin, which is standard for R. equi treatment, adds additional hepatic considerations since both drugs affect liver function. Baseline liver enzyme assessment and periodic monitoring during treatment may be recommended. Cardiac rhythm abnormalities may also warrant caution, as macrolides have been associated with QT prolongation in various species. Pregnant mares should avoid clarithromycin unless absolutely necessary, as safety in equine pregnancy is not established.

The intentional combination of clarithromycin with rifampin represents the standard therapeutic approach for Rhodococcus equi pneumonia rather than an adverse interaction. These drugs work synergistically against R. equi while preventing resistance development that occurs rapidly with rifampin monotherapy. However, both drugs affect hepatic function, and combined therapy may increase the potential for hepatotoxicity during prolonged treatment. Monitoring hepatic enzymes periodically during extended clarithromycin-rifampin therapy is prudent clinical practice.

Clarithromycin is a known inhibitor of cytochrome P450 3A4 enzymes in many species, which can significantly affect metabolism of drugs processed through this pathway. While equine-specific drug interaction data is limited, concurrent use of clarithromycin with medications metabolized by CYP3A4 may result in increased plasma concentrations and potential toxicity of those drugs. Veterinarians should review all concurrent medications when prescribing clarithromycin and adjust therapy as needed based on potential interactions.

Concurrent use of clarithromycin with other macrolide antibiotics such as azithromycin or erythromycin is not recommended, as this provides no therapeutic advantage while potentially increasing adverse effect risk. Similarly, combination with lincosamide antibiotics may result in antagonism at the ribosomal binding site. Switching between macrolide antibiotics should involve appropriate washout periods and clear rationale for the change rather than concurrent administration.

Antacids and medications containing aluminum, magnesium, or other cations may potentially affect clarithromycin absorption, though this interaction is less pronounced than with some other antibiotic classes. Separating administration of such products from clarithromycin doses helps ensure optimal drug absorption. Sucralfate and other gastrointestinal coating agents should similarly be administered at different times than clarithromycin.

Competition horses treated with clarithromycin must consider drug detection and withdrawal time implications, though this situation is uncommon since clarithromycin is primarily used in foals rather than performance animals. Any horse receiving clarithromycin should be withheld from competition until appropriate withdrawal time has elapsed, and consultation with a veterinarian familiar with competition drug regulations is advised. Complete medication records facilitate accurate withdrawal time calculation and regulatory compliance when foals eventually enter competition careers.

Monitoring during clarithromycin therapy should include regular assessment of temperature, respiratory status, appetite, nursing behavior, and manure consistency. Temperature monitoring is especially critical during warm weather given the risk of macrolide-associated hyperthermia in foals. Rectal temperature should be measured at least twice daily during treatment, with increased frequency during hot weather or if the foal shows any signs of heat stress. Immediate intervention including cooling measures and veterinary contact is essential if elevated temperature is detected.

Environmental management to prevent hyperthermia is mandatory for foals receiving clarithromycin. Access to shade must be available at all times during daylight hours. Turnout during peak heat hours should be avoided, and ideally foals should remain in well-ventilated or climate-controlled housing during the hottest portions of the day. Exercise should be minimized during treatment. Water availability must be ensured to support thermoregulation. Some breeding farms maintain foals in air-conditioned facilities throughout macrolide treatment during summer months.

Special populations requiring particular attention include very young foals, foals with failure of passive transfer or other immune compromise, and foals with concurrent illness. These patients may be at increased risk for both the underlying infection and adverse effects from therapy. Intensive monitoring and supportive care may be warranted. Foals receiving prolonged treatment courses should have periodic veterinary assessments to evaluate response, monitor for adverse effects, and determine appropriate treatment endpoints.

Administration precautions for clarithromycin include ensuring accurate dosing based on current body weight, maintaining consistent twelve-hour dosing intervals, and proper storage of oral suspension. The bitter taste of clarithromycin may cause some foals to resist medication administration, requiring patience and technique adaptation. Handlers should wash hands after administering medication as standard hygiene practice. Proper suspension preparation and storage according to manufacturer guidelines ensures drug stability throughout the treatment course.

Long-term use of clarithromycin, which is typical for complete R. equi treatment, necessitates ongoing monitoring for cumulative adverse effects. Hepatic function assessment through periodic bloodwork is recommended during extended clarithromycin-rifampin therapy. Serial thoracic ultrasound examinations monitor treatment response and help determine appropriate treatment duration. The decision to discontinue therapy should be based on resolution of clinical signs, ultrasound findings, and normalization of inflammatory markers rather than arbitrary treatment duration.

Clarithromycin tablets should be stored at controlled room temperature, typically between 59°F and 86°F (15°C to 30°C), protected from moisture and excessive heat. Original packaging provides appropriate protection from environmental factors affecting stability. In barn environments where temperature regulation may be inconsistent, storing medication in climate-controlled areas ensures drug integrity. Extended-release tablets have similar storage requirements to immediate-release formulations.

Oral suspension formulations of clarithromycin require specific attention to reconstitution and storage instructions. Dry powder for suspension should be stored according to manufacturer guidelines until reconstitution. After reconstitution with water, the suspension typically requires room temperature storage and has limited stability, usually fourteen days. Some formulations may require refrigeration; specific product labeling should be consulted. The reconstituted suspension should be shaken vigorously before each dose to ensure uniform drug distribution.

Safe handling of clarithromycin follows standard veterinary medication protocols. While clarithromycin does not pose significant risks from brief skin contact, hands should be washed after handling the medication or administering doses. Individuals with known macrolide allergies should avoid handling clarithromycin and have another caregiver administer doses. Spills of oral suspension should be cleaned promptly, and contaminated surfaces wiped clean.

Proper disposal of unused or expired clarithromycin supports environmental protection and prevents inappropriate use. Remaining medication after treatment completion should not be saved for future use without veterinary guidance, as treatment protocols should be individualized for each patient and episode. Veterinary clinics and pharmacies may accept unused medications for proper disposal. Community pharmaceutical take-back programs provide safe disposal options. Medication should not be disposed of by flushing down drains or placing in regular trash where environmental contamination or accidental exposure could occur.

Draft breed foals may require clarithromycin therapy when Rhodococcus equi infections occur, though R. equi incidence varies between farms and management systems rather than by breed specifically. Dosing for draft foals must account for their larger body mass compared to light breed foals of similar age. Accurate weight measurement is particularly important as draft foals may grow rapidly and visual estimation often underestimates actual weight. Larger foals require proportionally larger medication volumes, which may present practical administration challenges with oral suspension formulations.

Thoroughbred breeding farms represent the setting where clarithromycin use is most common due to high R. equi prevalence on many large operations with intensive foal management. The concentrated foal populations, environmental conditions, and stress associated with commercial breeding operations contribute to Rhodococcus transmission and disease expression. Thoroughbred foals on endemic farms may be monitored through screening programs allowing early detection and treatment initiation. The investment value of Thoroughbred foals supports intensive diagnostic and treatment protocols.

Warmblood and sport horse breeding operations also experience Rhodococcus equi infections and may require clarithromycin therapy for affected foals. Management practices on warmblood farms vary widely, and R. equi prevalence depends more on environmental factors and farm history than breed. Standard treatment protocols apply to warmblood foals with appropriate weight-based dosing calculations.

Ponies and miniature horse foals present specific considerations due to their smaller body size. Accurate dosing in small equines requires precise measurement, and oral suspension formulations facilitate appropriate dose calculation. The smaller body mass of miniature horse foals means that standard tablet sizes may require division or crushing for appropriate dosing. These smaller foals may dehydrate more rapidly if gastrointestinal adverse effects develop, necessitating vigilant monitoring. Breed-specific genetic conditions do not directly affect clarithromycin pharmacology, but overall health status of individual foals influences treatment approach and monitoring requirements.

Within the macrolide antibiotic class, azithromycin represents the primary alternative to clarithromycin for treating Rhodococcus equi pneumonia in foals. Both macrolides demonstrate similar efficacy when combined with rifampin for R. equi treatment, and selection between them often depends on availability, cost, and practical considerations such as dosing frequency. Azithromycin's once-daily or pulse dosing schedule may offer convenience advantages over clarithromycin's twice-daily administration, particularly for extended treatment courses. Erythromycin, the original macrolide used for R. equi, remains available but has largely been replaced by newer agents with improved tolerability profiles.

Rifampin must be discussed alongside clarithromycin as the mandatory combination partner for R. equi treatment. Rifampin provides excellent intracellular penetration and bactericidal activity against Rhodococcus but cannot be used alone due to rapid resistance development. The clarithromycin-rifampin or azithromycin-rifampin combination represents the standard of care for R. equi pneumonia, and deviation from combination therapy risks treatment failure and resistance emergence.

Alternative antibiotic classes for equine respiratory infections when macrolides are contraindicated include trimethoprim-sulfonamide combinations for many bacterial pathogens, beta-lactam antibiotics including penicillin preparations for susceptible organisms, and aminoglycosides for gram-negative infections requiring parenteral therapy. However, none of these alternatives achieve the intracellular concentrations necessary for effective R. equi treatment, making macrolides irreplaceable for this specific indication despite their risk profile in horses. Veterinary guidance ensures appropriate antibiotic selection based on confirmed or suspected pathogens, culture and sensitivity results, and individual patient factors.